JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mezey, K.
Right arrow Articles by Huertas-Lozano, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mezey, K.
Right arrow Articles by Huertas-Lozano, J.
Journal of Pharmacology And Experimental Therapeutics, Vol. 93, Issue 2, 223-229, 1948
Copyright © 1948 by American Society for Pharmacology and Experimental Therapeutics


NIAARA; A DIGITALIS-LIKE COLOMBIAN ARROW POISON

K. Mezey 1, C. Uribe-Piedrahita 2, J. Pataki 2, and J. Huertas-Lozano 2

1 Javeriana University Medical School, Bogotá
2 The César Uribe-Piedrahita Research Laboratories, Bogotá, Colombia, S. A.

1. Niaara, an arrow poison from Colombia, S. A. is the latex of the tree Ogcodeia ternstroemiiflora Midbr.

2. An amorphous principle ("niaarin") having chemical and pharmacological properties characteristic of the cardiac glycosides has been isolated from the latex of this tree. Neither the crude nor pure materials have any curariform activity.

3. The intravenous LD50 in cats is 0.21 mgm./kgm. It is poorly absorbed from the gastro-intestinal tract.

4. Seven cases of congestive heart failure in man were successfully treated with niaarin.

Submitted on March 2, 1948







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1948 by the American Society for Pharmacology and Experimental Therapeutics.